24/7 Market News Snapshot 04 September, 2025 – Soligenix, Inc. Common Stock (NASDAQ:SNGX)
DENVER, Colo., 04 September, 2025 (www.247marketnews.com) – (NASDAQ:SNGX) are discussed in this article.
Soligenix, Inc., a biopharmaceutical company at the forefront of developing therapies for rare diseases, is currently witnessing a notable surge in its stock performance, with pre-market shares rising by 14.29% to $3.520. This increase follows a closing price of $3.080 in the previous session, alongside a trading volume of 1.83 million, signaling heightened investor interest and market momentum. Traders are advised to monitor critical support levels near $3.00 and resistance points at $3.70, as any continuation of this bullish trend could lead to further gains. However, a decline below the $3.30 threshold may indicate a potential downturn.
In a significant development, the company has also announced a breakthrough in vaccine stability with its proprietary ThermoVax® technology. A recent manuscript highlights the long-term stability of ebolavirus vaccines, which have demonstrated efficacy at elevated temperatures of 40°C (104°F) over a two-year period. This achievement is a collaborative effort with Dr. Axel Lehrer of the John A. Burns School of Medicine and is set to be published in the journal Vaccine.
Dr. Lehrer remarked on the implications of these findings for vaccination strategies, particularly in endemic regions, emphasizing the benefits of a single-vial subunit vaccine capable of shipping without stringent cold chain requirements. Christopher J. Schaber, PhD, President and CEO of Soligenix, underscored the transformative potential of these thermostabilized vaccines in enhancing public health logistics and efficacy. These advancements reaffirm Soligenix’s commitment to addressing critical medical needs and advancing biopharmaceutical innovation on a global scale.
Related news for (SNGX)
- Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
- Soligenix Announces Closing of $7.5 Million Public Offering
- Soligenix Announces Pricing of $7.5 Million Public Offering
- Breaking News: MoBot’s Latest Update as of 09/23/25 07:00 AM
- Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor